217 related articles for article (PubMed ID: 37544710)
21. The third pandemic: The respiratory syncytial virus landscape and specific considerations for the allergist/immunologist.
Frenkel LD; Gaur S; Bellanti JA
Allergy Asthma Proc; 2023 Jul; 44(4):220-228. PubMed ID: 37236777
[No Abstract] [Full Text] [Related]
22. Structure-based design of a single-chain triple-disulfide-stabilized fusion-glycoprotein trimer that elicits high-titer neutralizing responses against human metapneumovirus.
Ou L; Chen SJ; Teng IT; Yang L; Zhang B; Zhou T; Biju A; Cheng C; Kong WP; Morano NC; Stancofski ED; Todd JP; Tsybovsky Y; Wang S; Zheng CY; Mascola JR; Shapiro L; Woodward RA; Buchholz UJ; Kwong PD
PLoS Pathog; 2023 Sep; 19(9):e1011584. PubMed ID: 37738240
[TBL] [Abstract][Full Text] [Related]
23. Structural basis for recognition of the central conserved region of RSV G by neutralizing human antibodies.
Jones HG; Ritschel T; Pascual G; Brakenhoff JPJ; Keogh E; Furmanova-Hollenstein P; Lanckacker E; Wadia JS; Gilman MSA; Williamson RA; Roymans D; van 't Wout AB; Langedijk JP; McLellan JS
PLoS Pathog; 2018 Mar; 14(3):e1006935. PubMed ID: 29509814
[TBL] [Abstract][Full Text] [Related]
24. Coexpression of respiratory syncytial virus (RSV) fusion (F) protein and attachment glycoprotein (G) in a vesicular stomatitis virus (VSV) vector system provides synergistic effects against RSV infection in a cotton rat model.
Brakel KA; Binjawadagi B; French-Kim K; Watts M; Harder O; Ma Y; Li J; Niewiesk S
Vaccine; 2021 Nov; 39(47):6817-6828. PubMed ID: 34702618
[TBL] [Abstract][Full Text] [Related]
25. Conformational Flexibility in Respiratory Syncytial Virus G Neutralizing Epitopes.
Fedechkin SO; George NL; Nuñez Castrejon AM; Dillen JR; Kauvar LM; DuBois RM
J Virol; 2020 Feb; 94(6):. PubMed ID: 31852779
[TBL] [Abstract][Full Text] [Related]
26. Monoclonal antibody based in vitro potency assay as a predictor of antigenic integrity and in vivo immunogenicity of a Respiratory Syncytial Virus post-fusion F-protein based vaccine.
Djagbare MD; Yu L; Parupudi A; Sun J; Coughlin ML; Rush BS; Sanyal G
Vaccine; 2018 Mar; 36(12):1673-1680. PubMed ID: 29456016
[TBL] [Abstract][Full Text] [Related]
27. Structure, Immunogenicity, and Conformation-Dependent Receptor Binding of the Postfusion Human Metapneumovirus F Protein.
Huang J; Chopra P; Liu L; Nagy T; Murray J; Tripp RA; Boons GJ; Mousa JJ
J Virol; 2021 Aug; 95(18):e0059321. PubMed ID: 34160259
[TBL] [Abstract][Full Text] [Related]
28. Identification of antibody neutralization epitopes on the fusion protein of human metapneumovirus.
Ulbrandt ND; Ji H; Patel NK; Barnes AS; Wilson S; Kiener PA; Suzich J; McCarthy MP
J Gen Virol; 2008 Dec; 89(Pt 12):3113-3118. PubMed ID: 19008400
[TBL] [Abstract][Full Text] [Related]
29. Engineering, Structure and Immunogenicity of the Human Metapneumovirus F Protein in the Postfusion Conformation.
Más V; Rodriguez L; Olmedillas E; Cano O; Palomo C; Terrón MC; Luque D; Melero JA; McLellan JS
PLoS Pathog; 2016 Sep; 12(9):e1005859. PubMed ID: 27611367
[TBL] [Abstract][Full Text] [Related]
30. Combinatorial F-G Immunogens as Nipah and Respiratory Syncytial Virus Vaccine Candidates.
Isaacs A; Cheung STM; Thakur N; Jaberolansar N; Young A; Modhiran N; Bailey D; Graham SP; Young PR; Chappell KJ; Watterson D
Viruses; 2021 Sep; 13(10):. PubMed ID: 34696372
[TBL] [Abstract][Full Text] [Related]
31. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
[TBL] [Abstract][Full Text] [Related]
32. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
[TBL] [Abstract][Full Text] [Related]
33. Structure-Based Design and Antigenic Validation of Respiratory Syncytial Virus G Immunogens.
Nuñez Castrejon AM; O'Rourke SM; Kauvar LM; DuBois RM
J Virol; 2022 Apr; 96(7):e0220121. PubMed ID: 35266806
[TBL] [Abstract][Full Text] [Related]
34. Effects of Alterations to the CX3C Motif and Secreted Form of Human Respiratory Syncytial Virus (RSV) G Protein on Immune Responses to a Parainfluenza Virus Vector Expressing the RSV G Protein.
Liang B; Kabatova B; Kabat J; Dorward DW; Liu X; Surman S; Liu X; Moseman AP; Buchholz UJ; Collins PL; Munir S
J Virol; 2019 Apr; 93(7):. PubMed ID: 30651356
[TBL] [Abstract][Full Text] [Related]
35. A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats.
Rostad CA; Stobart CC; Gilbert BE; Pickles RJ; Hotard AL; Meng J; Blanco JCG; Moin SM; Graham BS; Piedra PA; Moore ML
J Virol; 2016 Aug; 90(16):7508-7518. PubMed ID: 27279612
[TBL] [Abstract][Full Text] [Related]
36. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers.
Swanson KA; Settembre EC; Shaw CA; Dey AK; Rappuoli R; Mandl CW; Dormitzer PR; Carfi A
Proc Natl Acad Sci U S A; 2011 Jun; 108(23):9619-24. PubMed ID: 21586636
[TBL] [Abstract][Full Text] [Related]
37. Antibody recognition of the Pneumovirus fusion protein trimer interface.
Huang J; Diaz D; Mousa JJ
PLoS Pathog; 2020 Oct; 16(10):e1008942. PubMed ID: 33035266
[TBL] [Abstract][Full Text] [Related]
38. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
[TBL] [Abstract][Full Text] [Related]
39. Structural basis for ultrapotent antibody-mediated neutralization of human metapneumovirus.
Banerjee A; Huang J; Rush SA; Murray J; Gingerich AD; Royer F; Hsieh CL; Tripp RA; McLellan JS; Mousa JJ
Proc Natl Acad Sci U S A; 2022 Jun; 119(25):e2203326119. PubMed ID: 35696580
[TBL] [Abstract][Full Text] [Related]
40. Protective antigenic sites in respiratory syncytial virus G attachment protein outside the central conserved and cysteine noose domains.
Lee J; Klenow L; Coyle EM; Golding H; Khurana S
PLoS Pathog; 2018 Aug; 14(8):e1007262. PubMed ID: 30142227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
